Skip to contentB
Biolargo, Inc.
B
BLGOBiolargo, Inc. Q3 2021 · 10-Q
Revenue$712.00K$712.00K+6.9% vs Q3 2020 Net Income-$1.44M-$1.44MN/M vs Q3 2020 EPS Diluted-$0.01-$0.01N/M vs Q3 2020 Gross Profit$350,000−4.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biolargo, Inc. · CIK 880242 · Engraved from SEC EDGAR
Operating Cash Flowderived-$908,000N/M Margins · derivedGross margin49.2%−5.6 pt vs Q3 2020
Operating margin-204.4%+82.3 pt vs Q3 2020
Net margin-201.5%+157.3 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 15, 2021 · 46 d after period end